local_hospital

Alergologo Clinica Alergias Malaga Dr.Barceló

Address
C/ Pinzón, 10, 29001 Málaga, Spain

Alergologo Clinica Alergias Malaga Dr.Barceló - Allergy Treatment Center

Alergologo Clinica Alergias Malaga Dr.Barceló is a specialized clinical research center dedicated to advancing the treatment of allergic diseases through innovative immunotherapy approaches. The center focuses on evidence-based allergy care and participates in cutting-edge clinical trials to develop more effective therapeutic solutions for patients suffering from environmental allergies.

  • Subcutaneous allergen immunotherapy using polymerized allergen extracts for grass and olive tree allergies
  • Treatment of moderate-severe allergic rhinitis and rhinoconjunctivitis
  • Management of controlled mild-moderate allergic asthma in conjunction with rhinitis

The center's research expertise encompasses comprehensive allergy treatment protocols following ARIA classification guidelines for rhinitis and GEMA 5.0 standards for asthma management. Their clinical trial work specifically evaluates the efficacy and safety of polymerized allergen vaccines administered subcutaneously, representing an important advancement in the etiological treatment of allergic conditions. This research contributes to improving therapeutic options for patients with both intermittent and persistent allergic manifestations.

Site Overview

assignment
1
connected trial
corporate_fare
1
sponsor
science
7
IMPs

Activity Indicator

Last 6 months

0
Trials started
0
Trials started 6–12 months ago
1
Total trials linked
Low Activity
trending_flatStable0%
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status
lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
0
Sponsors (total)
1
Active sponsors
0

Sponsor Network

Top 10 by active trials.

No sponsors linked to active trials.

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

No repeated partnerships found.

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 567 other sites in Spain

description
Trial volume
1
Outperforms 1% of sites
public
Therapeutic diversity
1areas
Outperforms 1% of sites
groups
Sponsor diversity
1sponsors
Outperforms 1% of sites

Therapeutic Area Benchmark — Spain

Select a therapeutic area to compare against other sites in Spain.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Spain

Market Share

Country: Spain

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Alergologo Clinica Alergias Malaga Dr.Barceló

Trial Sponsor Phase Status Start Date End Date
Efficacy and safety of MG01 and T517 drug combination in patients with allergic rhinitis or rhinoconjunctivitis, with or without mild‑moderate asthmaInmunotek S.L.Phase IIINot RecruitingAug 2024

IMP list

lock Showing 1 of 7 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Allergen Extract From Dactylis Glomerata Pollen, Glutaraldehyde-Modified1Unknown2024-08-182024-08-18

Request feasibility information

Ask this centre about capacity, equipment and patient population.

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.